Chronic inflammatory demyelinating polyneuropathy (CIDP) is a chronic, rare autoantibody-driven disease that affects the peripheral nervous system, causing progressive muscle weakness, impaired motor function and sensory disturbances. It’s estimated that there are 5-7 cases of CIDP for every 100,000 individuals.
It’s estimated that there are 5-7 cases of CIDP for every 100,000 individuals.
National Organization for Rare Disorders
J&J’s approach to CIDP
Building on our legacy of innovation in neuroscience and immunology, we’re evaluating an immunoselective treatment approach designed to potentially address the underlying cause of the disease without impacting other immune functions. This investigational therapy is being studied across multiple auto- and alloantibody-driven diseases.